Indivior Pharmaceuticals, Inc.
Financial highlights
| Metric | FY 12/31/25 | FY 12/31/24 | FY 12/31/23 | FY 12/31/22 | FY 12/31/21 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $1.2 | $1.2 | $1.1 | $0.9 | — |
| Operating income | $0.3 | $<0.1 | -$0.2 | -$0.1 | — |
| Net income | $0.2 | $<0.1 | -$0.1 | -$<0.1 | — |
| Cash Flow Statement | |||||
| Free cash flow | -$0.1 | $<0.1 | -$0.3 | -$<0.1 | — |
| Share repurchases | $<0.1 | $0.2 | $<0.1 | $0.1 | — |
Shares outstanding 118.0M · Free float 93.1%
Annual filing data through FY ended December 31, 2025; float as of October 1, 2026.
Earnings
Other Coverage
September 28, 2026
QBook
Stronger demand supports expansion as pricing diverges
August 14, 2026
Industry Earnings Roundup
Healthcare Earnings: Demand Surges, Costs Bite Back
August 3, 2026
Deals
Indivior to Buy Supernus in All-Stock Merger
August 3, 2026
Deals
Indivior and Supernus to Combine in All-Stock Merger of Equals
June 30, 2026
Share Count Trends
Utilities Lead Quarterly Dilution as Materials Buybacks Gain